Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021-2026.

Future oncology (London, England) - 1 Oct 2023

Zhu Xinmei, Durbin Laura, Kanas Gena, Phiri Kelesitse, Keeven Katie, Clark Otavio, Nersesyan Knar, Aziez Amine, Stojadinovic Alexander, Bell Kelly F

Abstract excerpt

Aim: To estimate the incidence, prevalence and treated prevalence by line of therapy (LOT) for non-small-cell lung cancer (NSCLC) patients without driver mutations from 2021 to 2026. Materials & methods: Country-specific registry data for Western Europe were used to project incidence and prevalence of NSCLC; LOT information was obtained from CancerMPact® Treatment Architecture physician surveys. Results:...

Topics

Join the communities discussing this publication.

Carcinoma, Non-Small-Cell Lung
Europe
Incidence
Lung Neoplasms
Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37529892
DOI: 10.2217/fon-2023-0063

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021-2026.PMID 37529892Read ↗

Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020.Semantic proximity Read ↗

[Annual therapeutic advances in advanced non-small cell lung cancer in 2024].Semantic proximity Read ↗

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.Semantic proximity Read ↗

Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.Semantic proximity Read ↗

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.Semantic proximity Read ↗

Lung Cancer: Targeted Therapy in 2025Semantic proximity Read ↗

Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US.Semantic proximity Read ↗

Treatment Patterns Across Lines of Therapy for Advanced Non-Small Cell Lung Cancer in the United States.Semantic proximity Read ↗

Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry.Semantic proximity Read ↗

[Targeted therapies for non-small cell lung cancer : state of the art in 2021].Semantic proximity Read ↗

Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolution.Semantic proximity Read ↗

[Guidelines on clinical practice of molecular tests in non-small cell lung cancer in China (2024 version)].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.